BiotechTube
EveliQure Biotechnologies

EveliQure Biotechnologies

Vienna, Austria· Est.
eveliqure.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

Eveliqure Biotechnologies is a private, clinical-stage biotech leveraging a proprietary live attenuated Shigella platform to develop oral vaccines against diarrheal diseases. Its lead candidate, ShigETEC, is in Phase 2b development for shigellosis and ETEC, addressing a significant unmet need in endemic regions and the travel market. The company is led by a seasoned team with deep vaccine development experience and is backed by a strategically experienced board.

Infectious DiseaseGastrointestinal

Technology Platform

Proprietary platform based on a live, genetically attenuated Shigella vaccine strain engineered to be non-invasive and provide broad, serotype-independent protection. The platform is designed for oral administration and can be modified to express heterologous antigens from other pathogens, enabling multivalent vaccine development.

Funding History

1
Total raised:$4.2M
Seed$4.2M

Opportunities

A significant dual market exists: a large, addressable traveler's diarrhea market with potential for premium pricing, and a major public health need in LMICs supported by WHO priority and potential Gavi funding.
The oral, potentially low-cost, and broadly protective nature of the platform aligns perfectly with the needs of both markets.

Risk Factors

Key risks include clinical failure of the lead ShigETEC candidate in Phase 2b/3 trials, platform-specific risks related to immune response and manufacturing, and commercial risks including high competition for global health funding and the need to demonstrate clear advantage over existing traveler's diarrhea treatments.

Competitive Landscape

The competitive landscape for Shigella/ETEC vaccines includes other biotechs and non-profits (e.g., PATH, IVI) developing various candidates (subunit, conjugate, live attenuated). Eveliqure's broad-spectrum, oral, bivalent approach is a key differentiator. In the travel market, it would compete with antibiotics and hygiene measures rather than other vaccines.

More companies in Immunotherapy / Immuno-Oncology →More companies in Austria →